Why Gilead Sciences, Inc., Wynn Resorts Ltd., and Boston Scientific Corporation Are Today's 3 Worst Stocks

In the absence of any major economic data, the stock market continued to gain ground today, with the S&P 500 Index (SNPINDEX: ^GSPC  ) even ending at an all-time high. Three stocks, however, finished as standout laggards: Gilead Sciences (NASDAQ: GILD  ) , Wynn Resorts (NASDAQ: WYNN  ) , and Boston Scientific Corporation (NYSE: BSX  ) were each firmly in the red Monday. The S&P 500, for its part, tacked on 1 point, or less than 0.1%, to end at 1,951.

Shares of Gilead Sciences, whose flagship product, Sovaldi, treats hepatitis C, shed 4.1% today, as a new, deep-pocketed competitor threw its hat in the ring. Perhaps you've heard of Merck? Well, the $170 billion pharma giant was so impatient to jump-start a comprehensive hepatitis C treatment that it paid the highest ever premium in a health-care deal, according to Bloomberg, to acquire Idenix Pharmaceuticals today. The $3.85 billion acquisition rewarded Idenix investors to the tune of 229% today. Gilead Sciences, on the other hand, is now pressured to either lower the price of its $84,000 treatment or invest more heavily in Sovaldi to differentiate it from Merck's new combo offering.

Casino operators Wynn Resorts also had a rough day on Wall Street today, losing 2.9% by the ring of the closing bell. Wynn investors should count themselves lucky for the simple reason that the gaming company has firmly established itself in Macau, the 21st century's gambling capital of the world. But participating in China's exclusive and emerging gambling hotspot brings its own risks, and right now the biggest risk for investors is the possibility that the explosive growth in the region is slowing. After a decelerating month of revenue growth in May, Wells Fargo reported that Macau gaming revenue, by its estimates, continues to decelerate in early June.

An interventional coronary stent. Source: Boston Scientific

Lastly, shares of Boston Scientific fell 2.8% Monday, kicking off the week on a bearish note. While revenue at Boston Scientific has been trending steadily lower for years -- a phenomenon no investor wants to see -- there's no real, compelling reason behind today's slump. The health care sector happened to be the second-worst performer in the stock market today, so Boston Scientific was already fighting an uphill battle Monday, but its long-term prospects aren't quite as dire. The company acquired Bayer's interventional division for $415 million last month, which should create operational synergies and complement its own interventional division ("interventional" products treat blood flow issues).

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 09, 2014, at 9:15 PM, JPMaysMustang wrote:

    This article is misleading about the true nature of GILD market position with Hep-C treatments. Merck's acquisition gets it a drug that is in PHASE II trials, at LEAST one year away from marketing and distribution. The article makes it sound like Merck now has a direct competing drug ready to go. A lot of drugs fail in Phase II and Phase III. I don't think GILD will be adjusting the price or needing to differentiate anytime soon. Sovaldi is a CURE for Hep C in most cases. A cure does not need to differentiate itself. This was simply a major market over reaction.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2988202, ~/Articles/ArticleHandler.aspx, 10/22/2014 11:50:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement